Clinical Trials Logo

Filter by:
NCT ID: NCT06313944 Not yet recruiting - Alzheimer Disease Clinical Trials

German Registry of Alzheimer's Disease Treated With Transcranial Pulse Stimulation

GE-R-A-TPS
Start date: April 1, 2024
Phase:
Study type: Observational

This study will primarily investigate the safety and secondarily the effect and applicability of Transcranial Pulse Wave Stimulation (TPS) for the treatment of Alzheimer's disease in the context of a PMCF study (Post-Market Clinical Follow-up). The multicenter, prospective data collection should help to optimize the stimulation protocol, as well as to record frequent to occasional adverse effects of the product and cognitive, affective and subjective scores.

NCT ID: NCT06314061 Not yet recruiting - Diabetes Mellitus Clinical Trials

The Effect of Continuous Glucose Monitoring in Surgical Patients With Diabetes.

WARD-glucose
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The goal of this randomised controlled trial to investigate the effect of continuous glucose monitoring (CGM) compared to standard point-of-care (POC) blood glucose measurements in surgical patients with diabetes in patients. The main question it aims to answer is: • Can the use of the CGM device Dexcom G7 with real-time alerts on dysglycaemia increase the time in range for glucose levels as compared with standard monitoring with point-of-care blood glucose in surgical patients with diabetes? Participants will be asked to wear a CGM device (Dexcom G7, Dexcom Inc.) during their stay in the hospital. For patients in the intervention group, deviations of glucose levels will provide the nursing staff with alerts. All patients will receive standard care of their diabetes. The CGM device will be worn for up to 10 days or until discharge.

NCT ID: NCT06314269 Not yet recruiting - Clinical trials for Perioperative Complication

Incidence of Perioperative Cerebrovascular Stroke in Assuit University Hospitals , Hospital Based Study

Start date: April 1, 2024
Phase:
Study type: Observational

Stroke is the most common cause of disability in elderly people (over 65years of age) and the third most common cause of death in the world . The World Health Organization estimates that one in six people globally will suffer from stroke in their lifetime. Perioperative stroke is the most unwanted complication for patients, as well as for surgeons and anesthesiologists . The reported risk of perioperative stroke varies with the type of surgery. Its incidence is generally not high (approximate 0.1-1.9%) in non-cardiac, non-neurologic, and non-major surgery However, it may occur in up to 10% of patients undergoing high-risk cardiac or brain surgery . Patients with perioperative stroke are less likely to have a good functional outcome and have an eight-fold higher mortality compared with those without perioperative stroke

NCT ID: NCT06314399 Not yet recruiting - Clinical trials for Antibiotic Resistant Strain

Predictive Factors Associated to Bile Cultures and Antibiogram Resistance in Patients With Laparoscopic Cholecystectomy

BACILO
Start date: April 1, 2024
Phase:
Study type: Observational

The BACILO study was designed with the objective of having robust data on local epidemiological bacterial colonisation information on bile cultures with patients taken to laparoscopic cholecystectomy in our institution to find which predictive factors are associated with culture positivity and antibiotic resistance patterns. Secondary endpoints include evaluating demographical, clinical and surgical variables and establishing comparison between both positive and negative bile cultures and between antibiotic sensitive and resistant microorganism strain isolations.

NCT ID: NCT06314698 Not yet recruiting - Multiple Myeloma Clinical Trials

Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Start date: April 1, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).

NCT ID: NCT06315504 Not yet recruiting - Nephrotic Syndrome Clinical Trials

Circulating Factors in Nephrotic Syndrome

Start date: April 1, 2024
Phase:
Study type: Observational [Patient Registry]

A prospective observational study to investigate the treatment-associated changes of circulating factors associated with glomerular diseases among patients with de novo nephrotic syndrome admitted to hospital for a kidney biopsy.

NCT ID: NCT06316271 Not yet recruiting - Clinical trials for Hypertension,Essential

Endothelial Function in Prehypertension

Start date: April 1, 2024
Phase:
Study type: Observational

In the frame of this proposal investigators will test the hypothesis that high normal blood pressure (prehypertension; PreHT) induces systemic endothelial dysfunction and endothelial activation in both micro- and macrocirculation, reduces re-endothelialization potential of human endothelial progenitor cells (EPCs) and increases the level of endothelial extracellular vesicles (EVs), which are accompanied by increased oxidative stress level. Furthermore, initial vascular and left ventricle (LV) remodeling contributes to changes in systemic hemodynamics and may be influenced by altered regulatory role of renin-angiotensin system (RAS) and autonomic nervous system (ANS) in PreHT but otherwise healthy individuals. To distinguish high normal blood pressure effect from those considered normal or high, study will be performed in three groups of individuals: prehypertensive (BP 130-139/85-89 mmHg), hypertensive (stage I, BP 140-150/90-100 mmHg), and controls (BP less than or equal to 129/85 mmHg). Altogether, the impairment of normal vascular relaxation mechanisms, endothelial activation as well as vascular and LV remodeling could play crucial role in increased cardiovascular risk and CVDs incidence in PreHT individuals. Moreover, the prognostic significance of assessing endotehlial dysfunction in hypertension (as well as in PreHT) is yet to be established.

NCT ID: NCT06316284 Not yet recruiting - Clinical trials for Chronic Kidney Diseases

miRNA in Chronic Kidney Diseases

Start date: April 1, 2024
Phase:
Study type: Observational

Oxidative stress and endoplasmic reticulum (ER) stress play a key role in tubular damage in both acute kidney injury and chronic kidney disease (CKD). Oxidative stress in the kidneys promotes renal vascular remodeling and increases preglomerular resistance. These are key elements in hypertension, acute and chronic kidney injury, as well as diabetic nephropathy. Chronic renal hypoxia is highlighted as the final common pathway to end-stage renal disease (ESRD). MicroRNA molecules (miRNA) also play an important role in these processes. MicroRNAs (miRNAs) are regulators of gene expression and play a role in the progression of renal ischemia-reperfusion injury. Although the pathophysiological contribution of microRNAs (miRNAs) to kidney damage has also been highlighted, the effect of miRNAs on kidney damage under conditions of oxidative and ER stress remains understudied.

NCT ID: NCT06316375 Not yet recruiting - Clinical trials for Blunt Injury of Thorax

STUMBL Score as a Risk Stratification Tool for Management of Blunt Chest Trauma Patients

Start date: April 1, 2024
Phase:
Study type: Observational

The aim of this study is to assess validity of the STUMBL score in EGYPT for complications of blunt chest trauma without multi-trauma and immediate life-threatening injuries and identify patients at risk of in- hospital mortality or ICU admission and predict survival in both Assiut & Suez Canal University Hospitals.

NCT ID: NCT06316557 Not yet recruiting - Ischemic Stroke Clinical Trials

High-frequency rTMS on the Cerebellar to Improve Post-stroke Cognitive Impairment

HOPE
Start date: April 1, 2024
Phase: N/A
Study type: Interventional

The objective of this clinical trial is to investigate the effectiveness and safety of repetitive transcranial magnetic stimulation (rTMS) in the cerebellum for individuals with post-stroke cognitive impairment. Participants will undergo rTMS in the cerebellar hemisphere opposite the lesion site, once daily for a total of five days.